Each month, the not-for-profit French journal Prescrire publishes systematic, independent analyses of the available evidence regarding new drugs, newly authorised indications for drugs already on the market, and new forms or new dose strengths of existing drugs.

The goal is to select, amidst the multitude of new products, those which deserve to be added to the list of useful therapeutic options, or ought to be used in place of other drugs.

The annual Prescrire Awards recognise drugs, drug packaging and drug information singled out for notice by Prescrire's editorial staff. The Prescrire Awards for 2022 in Paris were announced on 1st February 2023.

 "Pilule d'Or" Awards 

The "Pilule d'Or" ("Golden Pill") is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available.

• No drug represented a major therapeutic advance
  

Honours List

Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.

• PAXLOVID° (nirmatrelvir + ritonavir) - Pfizer
   

Noteworthy

Drugs that are deemed "Noteworthy" provide a modest improvement in patient care.

• ONUREG° (azacitidine) - Bristol-Myers Squibb

For details, see:

> The Prescrire Awards for 2022
 

©Prescrire 1 March 2023

Source: "The Prescrire Awards" Prescrire International 2023; 32 (246): 80-81. Free.

Download the full article